Roth Capital Downgrades Galectin Therapeutics (GALT) to Sell

September 28, 2016 8:41 AM EDT
Get Alerts GALT Hot Sheet
Price: $1.01 -0.98%

Rating Summary:
    2 Buy, 3 Hold, 1 Sell

Rating Trend: Up Up

Today's Overall Ratings:
    Up: 23 | Down: 34 | New: 34
Trade GALT Now!
Join SI Premium – FREE

Get daily under-the-radar research with StreetInsider.com's Stealth Growth Insider Get your 2-Wk Free Trial here.

Roth Capital downgraded Galectin Therapeutics (NASDAQ: GALT) from Buy to Sell with a price target of $0.75.

For an analyst ratings summary and ratings history on Galectin Therapeutics click here. For more ratings news on Galectin Therapeutics click here.

Shares of Galectin Therapeutics closed at $2.47 yesterday.



Serious News for Serious Traders! Try StreetInsider.com Premium Free!

You May Also Be Interested In






Related Categories

Downgrades

Related Entities

Roth Capital

Add Your Comment